<DOC>
	<DOCNO>NCT02785068</DOCNO>
	<brief_summary>A phase 1b/2a study evaluate combination MM-151 + nal-IRI + 5-FU + Leucovorin RAS/RAF wild-type Metastatic Colorectal Cancer .</brief_summary>
	<brief_title>Evaluation MM-151 + Nal-IRI + 5-FU + Leucovorin RAS/RAF Wild-type Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Part 1 : Patients enrol determine maximum tolerate dose , safety tolerability MM-151 + nal-IRI + 5-FU + LV patient mCRC RAS/RAF wild-type . Part 2 : Patients enrol maximum tolerated dose MM-151 combination nal-IRI + 5-FU + LV characterize initial efficacy conjunction level irinotecan SN-38 measure tissue .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Patients must great 18 year age Patients must able provide inform consent Patients must KRAS/NRAS/BRAF wildtype colorectal cancer Willing abstain sexual intercourse use effective form contraception study 120 day follow last dose study therapy ) . This apply woman childbearing potential well fertile men partner Patients previous pelvic radiation treatment Patients pregnant lactate Patients untreated ( primary ) uncontrolled Central Nervous System ( CNS ) ( primary metastatic ) malignancy ; patient CNS metastases undergone surgery radiotherapy stable dose corticosteroid least 2 week whose disease stable prior first schedule day dose eligible trial . History second malignancy last 3 year ; patient prior history insitu cancer basal squamous cell skin cancer eligible . Patients receive recent antitumor therapy include standard chemotherapy radiation within 14 day bevacizumab within 28 day ( passed time actual anticipated toxicity ) prior first schedule dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Oncology</keyword>
	<keyword>RAS/RAF Wild-Type</keyword>
	<keyword>Nal-IRI</keyword>
	<keyword>EGFR Inhibitor</keyword>
	<keyword>Oligoclonal Antibody</keyword>
	<keyword>Nanoliposome</keyword>
	<keyword>Nanoliposomal Irinotecan</keyword>
</DOC>